Goldman C · 2026 · Cancer genomics & proteomics
Paper
BACKGROUND/AIM: Ewing sarcoma is a fusion-driven malignancy with low tumor mutational burden, making recurrent tumor-associated antigens with favorable tumor-to-normal contrast central to immunotherapy development. We converted the Deng et al. -defined 32-gene Ewing Sarcoma Specific Signature (ESS32) into a practical target atlas by integrating tumor RNA expression with normal-tissue context, protein evidence, subcellular localization, and therapeutic accessibility. MATERIALS AND METHODS: A 38-gene set was analyzed, including ESS32 and six comparator antigens (STEAP1, LINGO1, PRAME, CD99, CD276/B7-H3, and ENPP1). Eight Gene Expression Omnibus datasets ( n =854 samples) were assigned predefined roles spanning tumor- versus -skeletal-muscle comparison, broad normal-organ context, EWSR1::FLI1 perturbation, tumor-only support cohorts, cell-line models, and cross-sarcoma comparison. Results were overlaid with Human Protein Atlas and published proteomic/surfaceome evidence. RESULTS: In GSE17674, the strongest tumor-enriched transcripts included NKX2-2, NPY1R, STEAP1, RBM11, RNF182, LIPI, CD99, STEAP2, LOXHD1, and DCDC2. Normal-tissue and compartment data substantially reordered RNA-only ranking. NKX2-2 showed the strongest Ewing-associated signal but encodes a nuclear transcription factor, favoring peptide-HLA/T-cell receptor (TCR) or vaccine development. RBM11 and LIPI emerged as high-interest intracellular/secretome-associated candidates, with an explicit epididymal/male reproductive caveat for LIPI. CD99 and NPY1R illustrated normal-cell reservoir and receptor-distribution constraints. CONCLUSION: ESS32 should be interpreted as an EWSR1::FLI1-associated RNA discovery set, not as a pre-validated target panel. Practical nomination requires integration of RNA enrichment, normal-tissue distribution, protein evidence, cellular compartment, and modality compatibility before nomination of TCR, vaccine, antibody-drug conjugate (ADC), chimeric antigen receptor (CAR), radioligand, or validation-first candidates.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K
Xudong Wang; Jin Zhang
Hofmann M; Unverdorben F; Pszolla MG; Aschmoneit N; Hutt M; Manz T; Schuster H; Hukelmann J; Acs A; Tenkerian C; Missel S; Mølhøj M; Schräder C; Wagner C; Maurer D; Bunk S; Reinhardt C
Pan D; Kumar A; Lipof JJ; Chung A; Wolf JL; Martin TG 3rd; Arora S; Sayre PH; Chari A
Wang L; Gong S; Wang J; Bao Y; Mei N; Lu X; Chen W; Xi L; Zhang H; Chen X; Ning P; Fan X; Wang H
Pamenter G; Ovari G; Kulkarni A; Williams-Fegredo T; Knevelman C; Mitrophanous K; Davies L; Foroutan F; Townsend M; Goldrick S; Bracewell DG
Source record